[go: up one dir, main page]

Arizkane, 2022 - Google Patents

Impact of tyrosine kinase inhibitors and bone morphogenetic proteins on persistent leukemic stem cell dormancy in Chronic Myeloid Leukemia patients at remission

Arizkane, 2022

View PDF
Document ID
15050185312216309946
Author
Arizkane K
Publication year

External Links

Snippet

Despite the therapeutic progress of Chronic Myeloid Leukemia (CML) due to the Tyrosine Kinase Inhibitors (TKIs) that targets specifically BCR-ABL kinase, TKI treatment is not yet curative since many CML patients still retain leukemic stem cells (LSCs) and undifferentiated …
Continue reading at theses.hal.science (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation

Similar Documents

Publication Publication Date Title
Vokali et al. Lymphatic endothelial cells prime naïve CD8+ T cells into memory cells under steady-state conditions
Schatteman et al. Biology of bone marrow-derived endothelial cell precursors
RU2691062C2 (en) Reprogramming human endothelium in hematopoietic precursors of multiple lines of differentiation using certain factors
CA2540529C (en) Means and methods for the recruitment and identification of stem cells
Pick et al. Stress-induced cholinergic signaling promotes inflammation-associated thrombopoiesis
Ratajczak et al. Innate immunity derived factors as external modulators of the CXCL12-CXCR4 axis and their role in stem cell homing and mobilization
EP3191837A1 (en) Methods&compounds useful in hematopoietic stem cell medicine
US12109236B2 (en) Manipulating ARID5B expression in immune cells to promote metabolism, survival, and function
Adamiak et al. The P2X4 purinergic receptor has emerged as a potent regulator of hematopoietic stem/progenitor cell mobilization and homing—a novel view of P2X4 and P2X7 receptor interaction in orchestrating stem cell trafficking
Arizkane Impact of tyrosine kinase inhibitors and bone morphogenetic proteins on persistent leukemic stem cell dormancy in Chronic Myeloid Leukemia patients at remission
US20230226150A1 (en) Methods for use of an angiocrine factor in treating a patient exposed to a myeloablative insult
CN114174328A (en) GABA agonists and antagonists affect differentiation of hematopoietic stem cells and megakaryocytic progenitor cells
Casetti New roles of STAT5 factors in chronic myeloid leukemia cell maintenance
KR101590248B1 (en) Use of the TC1(C8orf4) gene regulating hematopoietic progenitor cells and hematopoiesis
Pereira Equine Endothelial Colony-Forming Cells: Phenotypic Enhancement and Ex Vivo Angiogenesis Studies
US20240366665A1 (en) Universal Receptor Immune Cell Therapy
Moore Investigating the interactions between bone marrow macrophages and acute myeloid leukaemia
Pensato The bitter taste receptors: a new mechanism of communication between leukemic cells and the microenvironment
Quarmyne Protein Tyrosine Phosphatase Receptor Type S (PTPRS) Regulates Hematopoietic Stem
Javier Increased TGF-β Signaling Drives Different Hematopoietic Disease Outcomes following Stress Hematopoiesis
Mora Pereira Equine Endothelial Colony-Forming Cells: Phenotypic Enhancement and Ex vivo Angiogenesis Studies
Bütow IKK2-inhibition targets TNF-induced leukemic stem cell persistence in chronic myeloid leukemia
Warsi Novel Insights into Haematopoietic Stem Cell Regulation and Function
Rörby Regulation of Hematopoietic Stem Cells
Sharkis STEM CELL PLASTICITY: WILL IT BE USEFUL TO REPAIR INJURY?